Patents Issued in October 4, 2016
  • Oil-in-water emulsified skin cosmetic
    Patent number: 9456965
    Abstract: The present invention is an oil-in-water emulsified skin cosmetic comprising acetylated hyaluronic acid, a specific polymethacryloyloxyethyl phosphorylcholine derivative, non-emulsifying cross-linked silicone, glycerin, polyvinyl alcohol, an acrylamide type thickener, and an oil component in an amount of 25 wt % or more relative to the total amount of the oil-in-water emulsified skin cosmetic. The object of the present invention is to provide an oil-in-water emulsified skin cosmetic manifesting superior effects in improving spreadability on the skin, absorption in the skin, absence of stickiness, emollient sensations, taut sensations, and wrinkles/sagging.
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: October 4, 2016
    Assignee: SHISEIDO COMPANY, LTD.
    Inventor: Takayuki Omura
  • Composition containing a cellulose derived capsule with a sunscreen
    Patent number: 9456966
    Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a bodywash, shampoo, conditioner, lotion, gel, soap, cream, hand sanitizer, spray or mousse and can be used by an individual during their normal hygiene processes, such as during a shower or bath or while applying a body product to their skin or hair.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: October 4, 2016
    Assignee: CoLabs International Corporation
    Inventor: Laura E. Cohen
  • Composition containing a cellulose derived capsule with a sunscreen
    Patent number: 9456967
    Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a bodywash, shampoo, conditioner, lotion, gel, soap, cream, hand sanitizer, spray or mousse and can be used by an individual during their normal hygiene processes, such as during a shower or bath or while applying a body product to their skin or hair.
    Type: Grant
    Filed: May 3, 2014
    Date of Patent: October 4, 2016
    Assignee: CoLabs International Corporation
    Inventor: Laura E. Cohen
  • Composition containing a cellulose derived capsule with a sunscreen
    Patent number: 9456968
    Abstract: A sunscreen composition comprised of one or more sunscreen active agents encapsulated in a cellulose derived capsule wherein the composition can contain one or more additional agents. A sunscreen composition can be mixed with a bodywash, shampoo, conditioner, lotion, gel, soap, cream, hand sanitizer, spray or mousse and can be used by an individual during their normal hygiene processes, such as during a shower or bath or while applying a body product to their skin or hair.
    Type: Grant
    Filed: May 3, 2014
    Date of Patent: October 4, 2016
    Assignee: CoLabs International Corporation
    Inventor: Laura E. Cohen
  • Scalp care composition
    Patent number: 9456969
    Abstract: A scalp care composition comprising from 1% to 99% of a volatile carrier; from 0.05% to 10% of a polymeric rheology modifier and mixtures thereof; from 0.03% to 1% of particulate scalp benefit agent wherein the composition is shear thinning and has (1) a zero shear viscosity value measured at 0.01 Pa of greater than about 1,500 Pa s; (2) a moderate stress viscosity value measured at 1 Pa viscosity of greater than about 1,000 Pa s; and (3) a high shear rate viscosity value measured at 100 l/s of less than about 0.5 Pa s.
    Type: Grant
    Filed: September 5, 2014
    Date of Patent: October 4, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Elizabeth Rebecca Aistrup, James Robert Schwartz
  • Dermatological compositions and methods
    Patent number: 9456970
    Abstract: Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: October 4, 2016
    Assignee: Upsher-Smith Laboratories, Inc.
    Inventors: Gloria A. Rood, Kenneth L. Evenstad, Victoria A. O'Neill
  • Moisturizer and cosmetic agent containing same
    Patent number: 9456971
    Abstract: Provided is a moisturizer having hygroscopicity and water retention ability, and also provided is a composition superior in antiseptic property and feeling on application, in addition to moisturizing property, and free of coloration and odorization. A moisturizer containing acylproline represented by the formula (1) wherein an acyl group represented by R1—CO— is an acyl group derived from a saturated or unsaturated fatty acid having 3-23 carbon atoms, or a salt thereof, and a composition containing (A) acylproline represented by the above formula (1) or a salt thereof and (B) bisphosphonate.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: October 4, 2016
    Assignee: AJINOMOTO CO., INC.
    Inventors: Takanori Sugimoto, Nana Haraya, Masatoshi Saito
  • Niacin-peptide having skin whitening activity and use for same
    Patent number: 9456972
    Abstract: Provided is niacin-peptide which has skin whitening activity. The peptide of the present invention has skin whitening activity by inhibiting melanogenesis, that is, by inhibiting the expression of a gene related to melanogenesis (for example, TRP-1, TRP2, or MIFT). The peptide of the present invention has high stability and skin permeability. Also provided is a cosmetic composition for skin whitening which contains the niacin-peptide.
    Type: Grant
    Filed: August 22, 2012
    Date of Patent: October 4, 2016
    Inventors: Sung-Ae Choi, Hyuk-Kwang Jeong, Young-Mi Byoun, Jun-Seob Shin, Seo Joon Yoo, Sang-Chul Yoo
  • Methionyl-methionine stereoisomers and use thereof in cosmetics
    Patent number: 9456973
    Abstract: The present invention relates to a cosmetic formulation comprising certain methionyl-methionine stereoisomers and to the use of methionyl-methionine for nail and/or hair treatment.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: October 4, 2016
    Assignee: EVONIK DEGUSSA GMBH
    Inventors: Mike Farwick, Matthias Mentel, Ursula Maczkiewitz, Andreas Seifert
  • Hair care compositions with selected protein hydrolysates and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines
    Patent number: 9456974
    Abstract: Hair treatment agents include selected protein hydrolysates and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: October 4, 2016
    Assignee: Henkel AG & Co. KGaA
    Inventors: Marcus Krueger, Jorg Kahre
  • Hair care compositions with selected amino acids and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines
    Patent number: 9456975
    Abstract: Hair treatment agents include selected amino acids and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: October 4, 2016
    Assignee: Henkel AG & Co. KGaA
    Inventors: Marcus Krueger, Jorg Kahre
  • Hair treatment compositions comprising selected UV filters and selected complexes of acidic protein hydrolysates and basic fatty acid amidoamines
    Patent number: 9456976
    Abstract: The present invention relates to hair treatment agents that include a synergistic combination of selected UV filters and selected complexes of acid protein hydrolysates and basic fatty acid amidoamines.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: October 4, 2016
    Assignee: Henkel AG & Co. KGaA
    Inventors: Marcus Krueger, Jorg Kahre
  • Cationized glycerolated cellulose
    Patent number: 9456977
    Abstract: A cationized glycerolated cellulose which, when blended in a hair cosmetic, is able to impart excellent smoothness and its long-lasting feeling at the time of rinsing and to impart a moist feeling and softness to the hair after drying and, when blended in a skin cleanser, is able to impart an excellent moisturizing feeling after drying; a surfactant composition containing the same; and a hair cosmetic composition and a skin cleanser composition each containing the surfactant composition, are provided. [1] A cationized glycerolated cellulose having a specified structure, which has a main chain derived from an anhydroglucose, wherein a degree of substitution of a cationized alkylene oxy group per the anhydroglucose unit is from 0.01 to 0.18, and a degree of substitution of a glycerol group per the anhydroglucose unit is from 0.5. to 5.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: October 4, 2016
    Assignee: KAO CORPORATION
    Inventors: Masaki Matsubara, Eisuke Miyoshi, Yumi Yamaguchi, Tomoko Uchiyama, Naoyuki Yamazaki, Ryosuke Fujii
  • Cosmetic compositions containing a silicone-organic polymer hybrid compound
    Patent number: 9456978
    Abstract: The present invention is directed towards a composition comprising, in a cosmetically acceptable carrier, at least one silicone-organic polymer hybrid compound; at least one nonionic film forming polymer; at least one amphoteric film forming polymer; and a neutralizer. The present invention also relates to methods for imparting shape to or maintaining the shape of hair wherein the composition provides style memory, strong hold and good shine, while at the same time, providing smoothness and a natural feel to the hair.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: October 4, 2016
    Assignee: L'OREAL
    Inventors: Aziza Suleiman, Clarissa Nogueira
  • Adminstration of intact mammalian cells to the brain by the intranasal route
    Patent number: 9456979
    Abstract: The present invention provides an intranasal method for delivery of intact mammalian cells to the brain for treatment of neurological deficits. This approach applies an intranasal instillation to directly administer cells to the brain, and is useful as therapy for patients with neurological deficit or those who may benefit from cellular therapy as a result of stroke, Alzheimer's, Parkinson's, diabetes, traumatic injury, surgery, cancer, or other diseases of the brain. This non-invasive method of delivering neuronal cells is desirable and safe.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: October 4, 2016
    Assignee: SRI INTERNATIONAL
    Inventors: Toufan Parman, Rebecca Erickson, Karen Steinmetz
  • Latanoprost-containing aqueous pharmaceutical composition
    Patent number: 9456980
    Abstract: The invention provides a latanoprost-containing aqueous pharmaceutical composition filled in a filter-equipped container, with the adsorption of latanoprost by the filter being prevented. In the latanoprost-containing aqueous pharmaceutical composition filled in the filter-equipped container, a nonionic surfactant is contained in the composition and the filter is made from at least one material selected from the group consisting of polyether sulfone, polyvinylidene fluoride, polycarbonate, and polytetrafluoroethylene.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: October 4, 2016
    Assignee: WAKAMOTO PHARMACEUTICAL CO., LTD.
    Inventors: Kohei Yoda, Satoshi Yamazaki, Emi Kawaguchi
  • Stable orally disintegrating tablets of hyoscyamine
    Patent number: 9456981
    Abstract: The present invention relates to stable orally disintegrating tablets of hyoscyamine or pharmaceutically acceptable salts thereof. The invention also relates to processes for the preparation of such tablets and use thereof.
    Type: Grant
    Filed: February 13, 2015
    Date of Patent: October 4, 2016
    Assignee: Cadila Healthcare Limited
    Inventors: Manish Chawla, Shailesh Biradar, Ajay Kumar Sharma
  • Solid formulations of niacin to counteract cold extremities
    Patent number: 9456982
    Abstract: The present invention describes the use of niacin lozenges to warm the extremities of a human that is subjected to cold environments, such as working in cold conditions, outdoor sports, fans watching sports, and other such exposure to cold. The lozenges have 50 to 150 mg of niacin to cause the extremities of the human to warm but without the flushing result from higher doses of niacin.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: October 4, 2016
    Assignee: BE-WARM LLC
    Inventor: Harvey Hoffenblum
  • Therapeutic composition with enhanced vessel targeting
    Patent number: 9456983
    Abstract: A composition that includes a bioactive agent-containing polymeric nanoparticle and a polymeric non-spherical microparticle, and methods of using such a composition to treat a vascular disease are disclosed.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: October 4, 2016
    Assignee: Advanced Cardiovascular Systems, Inc.
    Inventors: Syed Faiyaz Ahmed Hossainy, Florian Niklas Ludwig, Stephen D. Pacetti
  • Method for treating fibrosis using siRNA and a retinoid-lipid drug carrier
    Patent number: 9456984
    Abstract: What is described is a method for treating a fibrotic disease by administering a pharmaceutical composition comprising a drug carrier, which comprises a lipid and a retinoid, and a double-stranded nucleic acid molecule, which comprises an antisense sequence to mRNA encoding human hsp47.
    Type: Grant
    Filed: June 2, 2014
    Date of Patent: October 4, 2016
    Assignee: Nitto Denko Corporation
    Inventors: Yoshiro Niitsu, Victor Knopov, Joseph E. Payne, Richard P. Witte, Mohammad Ahmadian, Loren A. Perelman, Violetta Akopian, Yasunobu Tanaka, Elena Feinstein, Sharon Avkin-Nahum, Hagar Kalinski, Igor Mett, Kenjiro Minomi, Wenbin Ying, Yun Liu
  • Sustained-released product comprising a combination of a non-opioid amine and a non-steroidal, anti-inflammatory drug
    Patent number: 9456985
    Abstract: Sustained-release oral pharmaceutical compositions and methods of use, wherein the compositions are in a single dosage form and include an amine-containing compound (including salts thereof), a salt of a non-steroidal anti-inflammatory drug (NSAID), and a hydrophilic matrix.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: October 4, 2016
    Assignee: UPSHER-SMITH LABORATORIES, INC.
    Inventors: Christian F. Wertz, James S. Jensen, Victoria Ann O'Neill, Sean B. Mahoney, Stephen M. Berge
  • Naloxone mono preparation and multilayer tablet
    Patent number: 9456986
    Abstract: The present invention relates to a solid oral pharmaceutical composition comprising naloxone, or a pharmaceutically acceptable salt thereof, as an active substance, wherein the composition releases the active substance in a prolonged manner. In order to provide a composition that is suitable for an administration period of at least twelve-hours for the treatment of opioid-induced constipation, it is proposed that the composition should have an in vitro release rate of the active substance measured using the paddle stirrer method according to Ph. Eur. at 75 rpm in 500 ml 0.1 N hydrochloric acid at 37° C., of 0% to 75% in 2 h, of 3% to 95% in 4 h, of 20% to 100% in 10 h, of 30% to 100% in 16 h, of 50% to 100% in 24 h, and of more than 80% in 36 h, wherein the composition has a IC50/Cmax value of at least 40. In an alternative embodiment, the composition can be a multilayer tablet.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: October 4, 2016
    Assignee: Develco Pharma Schweiz AG
    Inventors: Hélène Rey, Olaf Mundszinger, Isabelle Golfier, Sylvia Jakob, Oliver Rusch
  • Capsule with internal diaphragm
    Patent number: 9456987
    Abstract: A capsule of, for instance, hard gelatin for holding a substance such as medicine, food supplements or similar materials includes a capsule body having a closed and an opposed open end with a predetermined length defined between the ends. A diaphragm having a closed end and an opposed open end and a predetermined length there between seals off the body and provides a first compartment to hold a first medicine, food supplement, etc. A cap is applied to the body as is conventional in capsules. The space between the inner portion of the cap and the diaphragm defines a second compartment for holding a second medicine, food supplement, etc. The contents of each compartment may be wet or dry (e.g., powder or liquid.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: October 4, 2016
    Assignee: Binutra, Inc.
    Inventors: Jacques Van Rooyen, Duncan E. B. Miller
  • Swallowable drug delivery device and methods of drug delivery
    Patent number: 9456988
    Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Some embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. The device comprises a capsule sized to be swallowed and pass through the intestinal tract. The capsule can include at least one guide tube, one or more tissue penetrating members positioned in the guide tube, a delivery member, an actuating mechanism and a release element. The release element degrades upon exposure to various conditions in the intestine so as to release and actuate the actuating mechanism. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: October 4, 2016
    Assignee: Rani Therapeutics, LLC
    Inventor: Mir Imran
  • Tamper-resistant oral opioid agonist formulations
    Patent number: 9456989
    Abstract: Methods of decreasing abuse potentials of oral opioid dosage forms are described. In the methods, an opioid antagonist in a substantially non-releasable form is included in oral dosage forms comprising an opioid agonist. When the dosage form is chewed, crushed, heated or dissolved in a solvent, and then administered orally, intranasally, parenterally or sublingually, the opioid antagonist is released and at least partially blocks effects of the opioid agonist. Methods of preparing oral opioid dosage forms having decreased abuse potential are also described.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: October 4, 2016
    Assignee: PURDUE PHARMA L.P.
    Inventors: Benjamin Oshlack, Curtis Wright, J.David Haddox
  • Multi-compartmented container
    Patent number: 9456990
    Abstract: The invention provides a multi-compartmented container suitable for the delivery of pharmaceuticals, medicines, vitamins, and the like.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: October 4, 2016
    Assignee: Capsugel Belgium NV
    Inventors: Clinton Wesley McInnes, Anna Marie Underwood, Phillip Andrew Vickery
  • Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
    Patent number: 9456991
    Abstract: The present disclosure relates to delayed release capsules and methods of manufacturing the capsules. The capsules comprise a capsule shell comprising a combination of gelatin and alginate, wherein the capsule shell encapsulates or is filled with at least one agent, and the delayed release capsules are chosen from soft capsules and hard capsules.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: October 4, 2016
    Inventor: Erik K Baes
  • Pharmaceutical composition comprising stable, amorphous, hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix forming component
    Patent number: 9456992
    Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
    Type: Grant
    Filed: January 11, 2013
    Date of Patent: October 4, 2016
    Assignee: XSPRAY MICROPARTICLES AB
    Inventors: Magnus Brisander, Mustafa Demirbüker, Gérald Jesson, Martin Malmsten, Helene Dérand
  • Compositions and methods for transdermal delivery of amphetamine
    Patent number: 9456993
    Abstract: Compositions for the transdermal delivery of amphetamine in a flexible, finite form are described. The compositions comprise a polymer matrix that includes amphetamine or a pharmaceutically acceptable salt or prodrug thereof and a backing layer comprising a polyurethane film layer and a polyester film layer, with a polyurethane adhesive disposed therebetween. Related methods also are described. Also described are compositions that exhibit a short onset period and a long duration of therapeutic effect.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: October 4, 2016
    Assignee: NOVEN PHARMACEUTICALS, INC.
    Inventor: Robert L. Lambert
  • Efficient process for the preparation of lycopene containing oleoresin and lycopene crystals for human consumption
    Patent number: 9456994
    Abstract: The present invention provides a process for the preparation of lycopene containing oleoresin and lycopene crystals for human consumption. The present invention provides an efficient process for the preparation of lycopene crystals from lycopene containing oleoresin with at least 85% by weight lycopene, containing at least 90% by weight trans-lycopene and trace amounts of cis-lycopene and other carotenoids. The production of commercial grade lycopene crystals with high content of trans-lycopene makes it ideal and suitable for human consumption, use as an anti-oxidant, for applications in prevention of cancer and macular degenerative diseases, as an anti-oxidant, and as a food/feed colorant. The process is simple, convenient, economical and commercially feasible.
    Type: Grant
    Filed: September 17, 2012
    Date of Patent: October 4, 2016
    Assignee: OmniActive Health Technologies Limited
    Inventors: T. K. Sunil Kumar, P. A. Sherena
  • Methods for inhibition of BNIP3 and prevention and treatment of ischemia reperfusion injury by tetra-O-methyl nordihydroguaiaretic acid
    Patent number: 9456995
    Abstract: Provided herein are methods for prevention and treatment of ischemia-reperfusion (IR) injury in the cardiac myocytes of a subject, by administration to the subject, a compound of formula I, or a salt, solvate, or stereoisomer thereof, in a sufficient amount either prior to, or during and/or after an ischemic event to mitigate or prevent IR injury to the cardiac tissue. Pharmaceutical compositions including the compound of formula I, or a salt, solvate, or stereoisomer thereof, and/or at least one additional therapeutic agent, are also provided.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: October 4, 2016
    Assignee: The Johns Hopkins University
    Inventors: Ru Chih Huang, Kotohiko Kimura
  • Formulations of dimethyl trisulfide for use as a cyanide antidote
    Patent number: 9456996
    Abstract: Dimethyl trisulfide antidote compositions may be used to as a cyanide poisoning antidote. Formulations of dimethyl trisulfide may be made in an aqueous solvent system that includes water and one or more of a co-solvent, a surfactant, a cyclodextrin, and a phospholipid.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: October 4, 2016
    Assignee: Sam Houston State University
    Inventors: Ilona Petrikovics, Kristof I. Kovacs
  • Selective inhibition of ?1-adrenergic receptors for the treatment of pediatric heart failure
    Patent number: 9456997
    Abstract: Provided are methods of treating heart failure in children using B1-selective adrenergic receptor antagonists, alone or in combination with other agents, including B-2-selective adrenergic receptor agonists.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: October 4, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
    Inventors: Brian Stauffer, Carmen Sucharov, Shelley Miyamoto
  • Selective inhibitors of undifferentiated cells
    Patent number: 9456998
    Abstract: Uses of a compound of any of Formulas I-VI as a cytotoxic inhibitor of undifferentiated cells are disclosed herein, as well as pharmaceutical compositions comprising a compound of any of Formulas I-VI, and methods for identifying a lead candidate for inhibiting undifferentiated cells. Further disclosed are uses of an SCD-1 inhibitor as a cytotoxic inhibitor of undifferentiated cells.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: October 4, 2016
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Hoffmann-La Roche Inc.
    Inventors: Uri Ben-David, Nissim Benvenisty, Payal Arora, Qing-Fen Gan, Ralph J. Garippa
  • Organosulfur compounds for the prevention and treatment of neurodegenerative diseases
    Patent number: 9456999
    Abstract: S-allylmercapto-N-acetylcysteine and related compounds are disclosed which can be administered in order to provide protection from the formation of aldehyde-protein adducts, protein carbonylation, protein aggregation, and the resulting neuroinflammation. Various neurodegenerative diseases which are suitable for treatment using these compounds include Alzheimer's disease, senile dementia, Parkinson's disease, multiple sclerosis, Lewy body disease, peripheral neuropathy, spinal cord injury, stroke and cerebral ischemia.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: October 4, 2016
    Assignee: Allium Vitalis, Inc.
    Inventor: David Michael Ott
  • Gamma-polyglutamic acid-based intraocular irrigation solutions
    Patent number: 9457000
    Abstract: Ophthalmic irrigating solutions are disclosed. The ophthalmic irrigating solution comprises: a) ?-polyglutamic acid (?-PGA) and/or salt thereof in an amount effective to increase the viscosity of the irrigating solution, and b) an ophthalmically acceptable aqueous vehicle for the ?-PGA and/or salt thereof. Also disclosed is a method of irrigating ocular tissues of a patient, in which the method comprises introducing to the ocular tissues of the patient an ophthalmic irrigating solution comprising ?-PGA) and/or salt thereof in an amount sufficient to irrigate the ocular tissues of the patient.
    Type: Grant
    Filed: June 16, 2013
    Date of Patent: October 4, 2016
    Assignee: NATIONAL HEALTH RESEARCH INSTITUTES
    Inventors: Yu-Chun Chen, Wen-Yu Su, Yen-Hsien Lee, Ko-Hua Chen, Feng-Huei Lin
  • Internal composition
    Patent number: 9457001
    Abstract: An object of the present invention is to provide an internal composition capable of exerting various physiological functions such as a brain-function improving function. That is, the present invention provides an internal composition including docosahexaenoic acid and capsanthin, or docosahexaenoic acid, capsanthin, lutein, and zeaxanthin as active ingredients.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: October 4, 2016
    Assignee: LION CORPORATION
    Inventors: Hiroki Takenaka, Yasuharu Ishihara, Naoki Ichiyanagi, Misato Koakutsu, Kei Kurita
  • Antimicrobial compositions comprising glyceryl nitrates
    Patent number: 9457002
    Abstract: Provided are antimicrobial solutions comprising a glyceryl nitrate (e.g., glyeryl trinitrate) in combination with a chelator (e.g., citrate), a peroxide, a fatty acid, and/or an alcohol (e.g., ethanol). In various aspects these components may synergistically act to kill or reduce the growth of microbes, such as bacteria or fungi, present in a biofilm.
    Type: Grant
    Filed: August 8, 2013
    Date of Patent: October 4, 2016
    Assignee: Board of Regents, The University of Texas System
    Inventors: Issam Raad, Joel Rosenblatt
  • Phenyl carbamate compound and a composition for preventing or treating a nerve gas-induced disease comprising the same
    Patent number: 9457003
    Abstract: The present invention relates to a composition for preventing or treating a nerve gas-induced disease comprising a phenyl carbamate compound and a method for preventing or treating a nerve gas-induced disease therewith. The present invention ensures the enhancement of neuroprotection, such that it is promising for preventing or treating various diseases caused by exposure to nerve gas.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 4, 2016
    Assignee: Bio-Pharm Solutions Co., Ltd.
    Inventor: Yong Moon Choi
  • Opsin-binding ligands, compositions and methods of use
    Patent number: 9457004
    Abstract: Compounds are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.
    Type: Grant
    Filed: August 13, 2015
    Date of Patent: October 4, 2016
    Assignee: BIKAM PHARMACEUTICALS INC.
    Inventor: David S. Garvey
  • Compositions and methods for increasing insulin sensitivity
    Patent number: 9457005
    Abstract: Methods and compositions for treating a blood glucose condition involve identifying a suitable subject and administering an effective amount of a composition that contains one or more of an opioid antagonist, an anticonvulsant, and a psychotherapeutic agent. The compositions can include insulin. In some embodiments, such methods and compositions can be used to modulate a blood glucose level. In preferred embodiments, such methods and compositions are useful for increasing a subject's sensitivity to insulin.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: October 4, 2016
    Assignee: OREXIGEN THERAPEUTICS, INC.
    Inventors: Michael A. Cowley, Anthony A. McKinney, Gary Tollefson
  • Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract
    Patent number: 9457006
    Abstract: A method of diagnosing in a subject for the purpose of determining if the subject's gastrointestinal contents has entered the subject's respiratory tract. The qualitative analysis can be also expanded into quantitative analysis, enabling the estimation of either the concentration, or the amount, or both, of the gastrointestinal contents that entered the respiratory tract. The invention also provides methods of treatment based on the identification of aspiration using the methods of the invention.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: October 4, 2016
    Assignees: Aradigm Corporation, The Regents of the University of California
    Inventors: Igor Gonda, Homer A. Boushey
  • Prenylflavanone compounds for modulating diabetes
    Patent number: 9457007
    Abstract: The present invention is directed to a novel use of prenylflavanone compounds for control of blood glucose and treatment or prevention of diabetes.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: October 4, 2016
    Assignee: NATUREWISE BIOTECH & MEDICALS CORPORATION
    Inventors: Chia-Nan Chen, Li-Ling Chi
  • Joint product comprising synephrine and topiramate
    Patent number: 9457008
    Abstract: The present invention provides a joint product comprising synephrine and topiramate, in which the synephrine or salt thereof is administered in form of rapid-release preparation, preferably rapid-release pellet, having daily dose of 2 mg to 25 mg, preferably 5 mg to 20 mg; the topiramate is administered in form of sustained-release or controlled-release preparation, preferably sustained-release pellet, having daily dose of 20 mg to 100 mg, preferably 23 mg to 92 mg. The composition is used for treatment of obesity or other diseases associated with obesity.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: October 4, 2016
    Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China
    Inventors: Song Li, Chunsheng Gao, Wu Zhong, Yuli Wang, Meiyan Yang, Li Shan, Xinbo Zhou, Zhibing Zheng, Xiaokui Wang
  • Methods and compositions for preventing and treating auditory dysfunctions
    Patent number: 9457009
    Abstract: The invention provides methods for treating auditory impairments in a subject in need of treatment comprising administering to said subject an effective amount of a composition comprising, as an active agent, one or more of a carboxy alkyl ester, a quinic acid derivative, a caffeic acid derivative, a ferulic acid derivative, or a quinic acid lactone or derivative thereof or pharmaceutically acceptable salt thereof and an acceptable carrier or excipient, so as to treat auditory impairments in the subject.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: October 4, 2016
    Assignee: THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventor: O'neil W. Guthrie
  • Compositions for use in treating or preventing metabolic stress-induced lung injury and methods for increasing physical capacity of mammalian livestock
    Patent number: 9457010
    Abstract: The present invention relates to a composition comprising (i) choline and (ii) a compound selected from the group consisting of palmitate, vitamin C and vitamin E for use in treating or preventing metabolic stress-induced lung injury and a method for increasing physical capacity of mammalian livestock comprising administering to the mammalian livestock the above composition.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: October 4, 2016
    Assignee: Nutri-fit GmbH & Co. KG
    Inventors: Michael Sobirey, Heinz Schneider
  • Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
    Patent number: 9457011
    Abstract: The present disclosure describes a treatment for acid related gastrointestinal disorders. The compounds described herein are known gastric acid secretion inhibitors in combination with alpha lipoic acid (ALA) or related compounds. ALA is not known as a treatment for acid related gastrointestinal disorders, however, ALA, when combined as described in the present disclosure with certain compounds used in the treatment of acid related gastrointestinal disorders, significantly improves existing treatments.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: October 4, 2016
    Inventor: Muslim D. Shahid
  • Transdermal absorption preparation
    Patent number: 9457012
    Abstract: A transdermal absorption preparation comprising (1) a support, and (2) a rubber-based adhesive layer comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof, oleic acid, capric acid and crotamiton, wherein the rubber-based adhesive layer is formed on a surface of the support. The transdermal absorption preparation exhibits excellent transdermal absorption of the 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or salt thereof.
    Type: Grant
    Filed: March 21, 2013
    Date of Patent: October 4, 2016
    Assignee: TEIKOKU SEIYAKU CO., LTD.
    Inventors: Masato Watanabe, Norihiro Kanayama
  • Method for treating a neurological disorder associated with hypoxia using a small moleucule MIF inhibitor
    Patent number: 9457013
    Abstract: Methods are provided for treating pathologies associated with hypoxia with an MIF inhibitor. Methods are also provided for treating a subject having, or at risk for pulmonary hypertension, with an MIF inhibitor. Methods are also provided for reating a subject having, or at risk from, a CNS disorder associated with hypoxia, with an MIF inhibitor. Methods are also provided of treating severe chronic lung disease, hypoxia-induced right ventricular hypertrophy or hypoxia-induced pulmonary vascular remodeling with an MIF inhibitor. Methods of diagnosing a subject with pulmonary hypertension are also provided.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: October 4, 2016
    Assignee: The Feinstein Institute for Medical Research
    Inventors: Edmund Miller, Yousef Al-Abed, Yinzhong Zhang, Kai Fan Cheng
  • Cysteine prodrugs
    Patent number: 9457014
    Abstract: Novel cysteine prodrugs and their use in the treatment of diseases and/or conditions, including but not limited to diseases and/or conditions of the Central Nervous System (CNS), including but not limited to schizophrenia, drug craving, drug addiction, bipolar disorder, anxiety, depression, Parkinson's disease, Alzheimer's disease, cognitive dysfunction, multiple sclerosis, Amyotrophic lateral sclerosis (ALS), ischemic stroke, HIV dementia, and Huntington's disease.
    Type: Grant
    Filed: July 30, 2012
    Date of Patent: October 4, 2016
    Assignee: Promentis Pharmaceuticals, Inc.
    Inventors: Daniel Lawton, Michael Neary, James A. Nieman